Expert Review of Endocrinology & Metabolism最新文献

Crinecerfont: emerging role in the management of congenital adrenal hyperplasia. crinererfont：在先天性肾上腺增生症治疗中的新作用。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-09-01 Epub Date: 2026-08-04 DOI: 10.1080/17446651.2026.2713482

Olga Fedorova, Henrik Falhammar

{"title":"Crinecerfont: emerging role in the management of congenital adrenal hyperplasia.","authors":"Olga Fedorova, Henrik Falhammar","doi":"10.1080/17446651.2026.2713482","DOIUrl":"10.1080/17446651.2026.2713482","url":null,"abstract":"Introduction: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a rare genetic endocrine disorder characterized by impaired cortisol synthesis, excessive adrenal androgen production, and elevated adrenocorticotropic hormone (ACTH) concentrations. The current standard of care involves supraphysiologic doses of glucocorticoids to suppress ACTH and manage androgen excess, often leading to long-term complications.Areas covered: A literature search of PubMed was conducted. This review critically examines the pharmacology, clinical efficacy, and potential role of crinecerfont in redefining CAH management.Expert opinion: Crinecerfont, a selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist, offers a novel therapeutic approach by targeting ACTH secretion at its hypothalamic origin. Recent Phase 2 and Phase 3 trials have demonstrated promising efficacy and safety across adult, adolescent, and pediatric populations. Crinecerfont may represent a promising adjunctive therapy in CAH management, addressing both biochemical control as well as quality of life and potentially long-term outcomes.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"317-326"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations. 雷司替龙和西马鲁肽治疗中东和北非地区mald患者：专家小组建议。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-09-01 Epub Date: 2026-07-03 DOI: 10.1080/17446651.2026.2698115

Yasser Fouad, Khalid M AlNaamani, Fatheya Alawadi, Abdulla Al Hassani, Nawal Alkhalidi, Bilal Hotayt, Faisal Abaalkhail, Samir Rouabhia, Maheeba Abdulla, Munira Y Altarrah, Mohamed Tahiri, Meriam Sabbah, Faisal M Sanai, Necati Ormeci, Gamal Esmat, Mohammed Eslam

{"title":"Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations.","authors":"Yasser Fouad, Khalid M AlNaamani, Fatheya Alawadi, Abdulla Al Hassani, Nawal Alkhalidi, Bilal Hotayt, Faisal Abaalkhail, Samir Rouabhia, Maheeba Abdulla, Munira Y Altarrah, Mohamed Tahiri, Meriam Sabbah, Faisal M Sanai, Necati Ormeci, Gamal Esmat, Mohammed Eslam","doi":"10.1080/17446651.2026.2698115","DOIUrl":"10.1080/17446651.2026.2698115","url":null,"abstract":"Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) affects 25-30% of the global population, with the Middle East and North Africa (MENA) region showing some of the highest prevalence rates, reaching up to 40%. MAFLD is a common cause of cirrhosis and hepatocellular carcinoma and is a leading indication for liver transplantation in this region. Hitherto, there have been no specific pharmacotherapies for MAFLD. However, the recent conditional approval of resmetirom and semaglutide by the FDA for the treatment of non-cirrhotic moderate-to-advanced (fibrosis stages 2 or 3) metabolic-associated steatohepatitis (MASH) offers a much-needed therapeutic option for this largely underserved condition.Areas covered: An expert panel from the MENA region conducted a comprehensive literature search via PubMed and Google Scholar, focusing on clinical trials and international guidelines for resmetirom and semaglutide. This review identifies the target treatment population, proposes criteria for cessation of therapy, outlines monitoring protocols, and addresses regional knowledge gaps.Expert opinion: The approval of the first two drugs for MASH is a milestone. Access to and affordability of these therapies will be the crucial determinants of their actual adoption. Future efforts should consider individualized treatment pathways stratified by cost, regulatory status, and healthcare infrastructure, while generating further regional evidence.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"357-365"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148374996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues. 雷司替龙和西马鲁肽：代谢性脂肪性肝炎的新一代治疗方法。机遇、挑战和问题。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-09-01 Epub Date: 2026-08-04 DOI: 10.1080/17446651.2026.2714267

Luigi E Adinolfi, Aldo Marrone, Antonio Izzi, Antonio Craxi

{"title":"Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.","authors":"Luigi E Adinolfi, Aldo Marrone, Antonio Izzi, Antonio Craxi","doi":"10.1080/17446651.2026.2714267","DOIUrl":"10.1080/17446651.2026.2714267","url":null,"abstract":"Introduction: Resmetirom and semaglutide are the first drugs to be approved for the pharmacological treatment of metabolic-associated steatohepatitis (MASH) and moderate-to-severe liver fibrosis. However, approval was based on histological endpoints obtained during a relatively short trial period, leaving some important questions unanswered.Areas covered: Resmetirom acts directly on the liver by activating thyroid hormone receptor β. Semaglutide acts systemically, reducing weight and improving metabolism. Both drugs induce resolution of MASH and improve liver fibrosis in a significant proportion of patients. The drugs are generally well tolerated, but significant gastrointestinal side effects can occur. Patient selection for treatment and efficacy evaluation should be based on noninvasive tests (NITs), but a substantial unresolved issue remains. Further issues include monitoring and the duration of treatment, as well as the impact of treatment on hepatic and systemic disease outcomes. Ensuring fair access to treatment for all is a challenge facing the global health community.Expert opinion: This review explores the current approach to issues and challenges associated with using resmetirom and semaglutide in patients with MASH, proposing reference points to assist physicians in their clinical practice. Furthermore, we emphasize the importance of implementing interventions within the healthcare system to ensure equitable access to therapies.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"367-378"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Opioid-induced adrenal insufficiency: diagnosis and management. 阿片类药物引起的肾上腺功能不全：诊断和管理。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-09-01 Epub Date: 2026-08-11 DOI: 10.1080/17446651.2026.2716201

Diane Donegan, Irina Bancos

{"title":"Opioid-induced adrenal insufficiency: diagnosis and management.","authors":"Diane Donegan, Irina Bancos","doi":"10.1080/17446651.2026.2716201","DOIUrl":"10.1080/17446651.2026.2716201","url":null,"abstract":"Introduction: Opioid-induced adrenal insufficiency (OIAI) is a known, but often overlooked complication associated with chronic opioid use. It is important to recognize OIAI as, if untreated, can lead to increased morbidity and mortality.Areas covered: This narrative review discusses the prevalence, pathophysiology, diagnosis, and management of OIAI, with special emphasis on the current challenges. While investigations and treatment of OIAI is similar to other causes of adrenal insufficiency, it is important to recognize and test for other opioid-induced endocrinopathies. Furthermore, unlike some causes of adrenal insufficiency, OIAI has demonstrated reversibility following the discontinuation of opioids; therefore, cessation of opioids should be considered as a part of a multidisciplinary collaboration.Expert opinion: Identification and appropriate treatment of patients with OIAI is important. Although recognition of this condition is increasing, further investigation is needed to identify additional risk factors to allow close follow-up of those at risk of OIAI or minimize the development OIAI.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"379-386"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do women with young-onset type 2 diabetes have a higher risk for adverse pregnancy outcomes? 年轻发病的2型糖尿病女性是否有更高的不良妊娠结局风险？

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-09-01 Epub Date: 2026-07-22 DOI: 10.1080/17446651.2026.2707297

Christine P Field, Kartik K Venkatesh

引用次数: 0

Improving outcomes through early diagnosis and care in diabetes during pregnancy: are we doing enough? 通过妊娠期糖尿病的早期诊断和护理改善结局：我们做得够吗？

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-09-01 Epub Date: 2026-07-24 DOI: 10.1080/17446651.2026.2707565

Annunziata Lapolla, Elisabetta Torlone

{"title":"Improving outcomes through early diagnosis and care in diabetes during pregnancy: are we doing enough?","authors":"Annunziata Lapolla, Elisabetta Torlone","doi":"10.1080/17446651.2026.2707565","DOIUrl":"10.1080/17446651.2026.2707565","url":null,"abstract":"Introduction: The prevalence of preexisting type 1 and type 2 diabetes in pregnancy continues to rise, with women with type 2 facing adverse maternal and fetal outcomes comparable to those with type 1. Despite international guidelines emphasizing a comprehensive, multi-targeted approach to ensure safe pregnancy outcomes, pregnancy-related complications remain substantially elevated in this population.Areas covered: This perspective article examines critical issues in the management of diabetes during pregnancy, identifying key barriers and evidence-based strategies to optimize suitable care. A search of the medical literature was performed, giving priority to randomized controlled trials (RCT), systematic reviews and meta-analyses. By analyzing the current evidence, we address fundamental challenges in preconception counseling, metabolic control optimization and pharmacological management.Expert opinion: The knowledge of these critical points is essential to improving maternal and neonatal outcomes and to reducing predictable complications in pregnant women with preexisting diabetes.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"327-340"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting kidney disease in type 1 diabetes: progress and promise. 针对1型糖尿病肾脏疾病：进展和前景。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-09-01 Epub Date: 2026-08-05 DOI: 10.1080/17446651.2026.2714265

Marcel H A Muskiet, David Z I Cherney

{"title":"Targeting kidney disease in type 1 diabetes: progress and promise.","authors":"Marcel H A Muskiet, David Z I Cherney","doi":"10.1080/17446651.2026.2714265","DOIUrl":"10.1080/17446651.2026.2714265","url":null,"abstract":"Introduction: Chronic kidney disease (CKD) affects ~30-40% of people living with type-1 diabetes (T1D) and remains a major driver of cardiovascular morbidity, kidney-failure, and premature mortality. Despite advances in diabetes-technologies, kidney-protective pharmacotherapy in T1D has remained largely unchanged since the introduction of renin-angiotensin-system (RAS)-inhibition >30 years ago. In contrast, CKD-treatment in type-2 diabetes (T2D) has been transformed by sodium-glucose co-transporter (SGLT)-inhibitors, glucagon-like peptide (GLP)-1-based therapies, and nonsteroidal mineralocorticoid receptor antagonists. Exclusion of people with T1D from these pivotal trials created a critical evidence-gap.Areas covered: We synthesizes mechanistic-/clinical evidence supporting a paradigm shift in kidney-protection for T1D. Literature searches of PubMed/MEDLINE, Embase, Web of Science, and ClinicalTrials.gov identified relevant English-language publications and ongoing studies through March 2026. We describe how the evolving T1D-phenotype, characterized by rising obesity and cardiometabolic dysfunction, strengthening the rationale for therapeutic translation. We critically evaluate current standards-of-care, unmet needs, and the renoprotective potential and safety of SGLT-inhibitors, GLP-1-based therapies, and finerenone in T1D, highlighting the pivotal FINE-ONE trial and albuminuria as a bridging biomarker for regulatory translation.Expert opinion: CKD-management in T1D is entering a long-overdue phase of therapeutic renewal. Ongoing trials, 'pillar'-strategies, validated surrogate endpoints, precision-medicine, and multidisciplinary care may finally enable meaningful modification of CKD-trajectories.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"341-355"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic aspects of polycystic ovary syndrome. 多囊卵巢综合征的代谢方面。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-07-01 Epub Date: 2026-05-04 DOI: 10.1080/17446651.2026.2656240

Dimitrios Pappas, Eleni Kandaraki, Aikaterini Kalogirou, Evanthia Diamanti-Kandarakis

{"title":"Metabolic aspects of polycystic ovary syndrome.","authors":"Dimitrios Pappas, Eleni Kandaraki, Aikaterini Kalogirou, Evanthia Diamanti-Kandarakis","doi":"10.1080/17446651.2026.2656240","DOIUrl":"10.1080/17446651.2026.2656240","url":null,"abstract":"Introduction: Polycystic ovary syndrome (PCOS) is a prevalent multisystem disorder with major reproductive and metabolic consequences. Understanding the interconnected molecular pathways linking insulin resistance (IR), hyperinsulinemia, and hyperandrogenism is crucial, as these mechanisms form the foundation for effective clinical management and targeted therapeutic strategies.Areas covered: This review examines current evidence on the metabolic underpinnings of PCOS, focusing on how IR and compensatory hyperinsulinemia alter ovarian steroidogenesis, impair granulosa cell aromatase activity, and disrupt follicular development. We summarize downstream systemic consequences-including dyslipidemia, impaired glucose tolerance, cardiovascular risk, and nonalcoholic fatty liver disease-while integrating emerging data on environmental disruptors, oxidative stress, and adipose tissue dysfunction. Literature was identified through a comprehensive search of PubMed, Scopus, Google Scholar, and ScienceDirect for studies published between 1985 and 2025, including clinical, experimental, and mechanistic work relevant to metabolic aspects of PCOS.Expert opinion: Clarifying the metabolic and endocrine mechanisms driving both reproductive and systemic dysfunction provides a critical basis for developing targeted therapies capable of improving ovulatory function and long-term cardiometabolic outcomes. Deepening mechanistic insight remains essential for advancing individualized and integrative treatment approaches in this heterogeneous and evolving syndrome.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"253-269"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The relationship between iron deficiency and thyroid function: findings from a population-based study in Jordan. 缺铁与甲状腺功能之间的关系：来自约旦一项基于人群的研究结果。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-07-01 Epub Date: 2026-06-30 DOI: 10.1080/17446651.2026.2686629

Nour Abdo, Asma'a Alselwi, Muna Ebbini, Shahd Al-Tawiel, Nahla Khawaja, Yousef Khader, Mohammed El-Khateeb, Kamel Ajlouni

{"title":"The relationship between iron deficiency and thyroid function: findings from a population-based study in Jordan.","authors":"Nour Abdo, Asma'a Alselwi, Muna Ebbini, Shahd Al-Tawiel, Nahla Khawaja, Yousef Khader, Mohammed El-Khateeb, Kamel Ajlouni","doi":"10.1080/17446651.2026.2686629","DOIUrl":"10.1080/17446651.2026.2686629","url":null,"abstract":"Background: This study aimed to examine the association between iron deficiency (ID) and thyroid dysfunction among Jordanian adults.Research design and methods: A cross-sectional analysis was conducted using data from 3,605 participants in a 2017 nationwide survey covering all 12 Jordanian governorates. Sociodemographic, anthropometric, and biochemical data were collected, including serum ferritin, thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4). Participants were categorized as having iron deficiency (ID), iron deficiency anemia (IDA), or control group (CG). Kruskal-Wallis and chi-square tests were used, with p < 0.05 considered significant.Results: Individuals with ID and IDA had significantly lower FT3 and FT4 levels and higher TSH levels compared to CG. The prevalence of hypothyroidism and combined hypothyroidism plus subclinical hypothyroidism was higher in the IDA group (p = 0.0011 and p = 0.0126, respectively). No significant associations were observed for hyperthyroidism or subclinical hyperthyroidism.Conclusion: Iron deficiency, particularly IDA, was associated with an increased prevalence of hypothyroidism among Jordanian adults. These findings highlight the importance of thyroid function screening in individuals with low iron status and underline the need for longitudinal studies to clarify causal pathways.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"307-312"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148360151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is the role of amylin as an emerging therapeutic agent in obesity? 胰淀素作为一种新兴的治疗肥胖症的药物有什么作用？

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-07-01 Epub Date: 2026-05-07 DOI: 10.1080/17446651.2026.2668391

Guillaume Bogaerts, Greta Lommi, Thomas A Lutz

引用次数: 0